Pharmaceutical stocks are in high demand among our clients. Traded volumes boomed in July, assisted by renewed optimism for the development of a COVID-19 vaccine alongside wealthy governments scrambling to lock up forward-looking supply agreements.
After months of declining volumes attributable to the worldwide economic contraction experienced, interest in pharmaceutical companies has rallied once again. Over the coming months, expect to continue to see pharmaceutical stocks in the spotlight, as the race towards a COVID-19 vaccine intensifies.
| Company | Ticker | Margin % | Exchange | Market Cap | YTD Return |
| Opko Health | OPK | 30% | NASDAQ | 3.590B | 264.63% |
| Paratek Pharmaceuticals | PRTK | 35% | NASDAQ | 194.526M | 11.91% |
| Pfizer | PFE | 10% | NYSE | 213.250B | -2.02% |
| Recce Pharmaceuticals | RCE | 35% | ASX | 201.115M | 284.72% |
| Mayne Pharma | MYX | 35% | ASX | 638.046M | -12.64% |
Download List of Single Stock CFDs
US-based Opko Health is a wide-scaling medical company, focusing recently on the COVID-19 outbreak. Off the back of selling their COVID-19 molecular kits, Opko has seen revenue increase by 33%. The company have also released an antibody test.
Paratek Pharmaceuticals is a large commercial-stage bio-pharmaceutical company focused on the development of innovative life-saving therapies for deadly diseases or other public health threats for civilian, government and military use.
Pfizer is one of the largest multi-national pharmaceutical companies in the world. It focuses on the development and production of new and improved medicines and vaccines for a wide scope of conditions.
Recce Pharmaceuticals 
is focused on developing products to fight global health threats. Recently, the company struck a deal with US firm Path BioAnalytics to test their new antibiotics against SARS-CoV-2.
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, providing patients with access to better and more accessible medicines. It also provides contract development and manufacturing services to more than 100 clients worldwide.
Disclaimer:This material is provided to you by Invast Global is solely for informational purposes, is intended for your use only and does not constitute an offer or commitment, a solicitation of an offer or comment, or any advice or recommendation, to enter into or conclude any transaction. Please refer to our PDS available on our website for further information.
Share this article:
